Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis El metabolismo posprandial de los triglicéridos se modifica por el polimorfismo...
Journal Information
Vol. 15. Issue 4.
Pages 147-152 (January 2003)
Share
Share
Download PDF
More article options
Vol. 15. Issue 4.
Pages 147-152 (January 2003)
Full text access
El metabolismo posprandial de los triglicéridos se modifica por el polimorfismo presente en el exón 1 del gen del receptor scavenger clase B tipo I
Postprandial triglyceride metabolism is modified by poymorphism of exon 1 of the class b type e scavenger receptor gene
Visits
3851
P. Pérez-Martínezaa,1
Corresponding author
fperezjimenez@uco.es

Correspondencia: Dr. F. Pérez-Jiménez. Unidad de Lípidos y Arteriosclerosis. Hospital Universitario Reina Sofía. Avda. Menéndez Pidal, s/n. 14004 Córdoba. España.
, C. Bellidoaa, J.A Morenoaa, P. Gómezaa, R. Morenoaa, C. Marínaa, J. López-Mirandaaa, F. Pérez-Jiménezaa, J.M. Ordovásbb
a Unidad de Lípidos y Arteriosclerosis. Hospital Universitario Reina Sofía. Córdoba. España
b Lipid Metabolism Laboratory, J.M. USDA Human Nutrition Research Centre on Aging. Tufts University. Boston, MA. Estados Unidos
This item has received
Article information
Fundamento

Recientemente se ha descrito que los portadores del alelo minoritario 2 (1/2) en el exón 1 del gen del receptor scavenger clase B tipo I (SR-BI) son más susceptibles a la presencia de grasa saturada en la dieta, con un mayor aumento del colesterol ligado a lipoproteínas de baja densidad (cLDL). Nuestro objetivo es determinar si dicho polimorfismo puede influir también en el metabolismo lipoproteico posprandial, ya que se ha señalado que puede mediar en la absorción intestinal de los triglicéridos.

Diseño y métodos

Se seleccionó a 47 voluntarios normolipémicos, homocigotos para el alelo e3 de la apolipoproteína (apo) E —37 homocigotos para el alelo 1 del SR-BI (1/1) y 10 heterocigotos para el alelo 2 (1/2)—. Recibieron una comida grasa (1 g/kg de peso corporal, 60.000 unidades de vitamina A por m2 de superficie corporal y 7 mg de colesterol/kg de peso), con un 60% de calories como grasa, un 15% como proteínas y un 25% como hidratos de carbono. Se realizaron extracciones en el tiempo 0 y cada hora hasta las 6 h y otras dos últimas a las 8,5 y 11 h, determinándose el colesterol, los triglicéridos, la apo A-I y la apo B.

Resultados

Se observó una interacción entre el polimorfismo presente en el exón 1 del gen del SRBI y los valores de triglicéridos totales en function del tiempo (p = 0,029). Así, los portadores del alelo 2 (1/2) presentaron una curva más retrasada, lo que indica una absorción intestinal más lenta de triglicéridos que los homocigotos 1/1.

Conclusiones

Nuestros datos indican que los portadores del alelo minoritario 2, con genotipo 1/2, presentan una absorción intestinal retrasada de triglicéridos. Esto podría explicar parte de la diferencia interindividual en la respuesta lipémica posprandial.

Palabras clave:
Receptor scavenger clase B tipo I
Lipemia posprandial
Genética
Riesgo cardiovascular
Background

Carriers of the minority allele 2 (1/2) in exon 1 of the scavenger receptor class B type I (SR-BI) gene have recently been reported to be more susceptible to the presence of saturated fat in diet, with a greater increase in low-density lipoprotein cholesterol. The aim of this study was to determine whether this polymorphism can also influence postprandial lipoprotein metabolism, since it has been described as a possible mediator in intestinal triglyceride absorption.

Design and methods

Forty-seven normolipidemic volunteers who were homozygotes for the e3 allele of apolipoprotein (apo) e were selected [37 homozygotes for allele 1 of the SR-BI (1/1) gene and 10 heterozygotes for allele 2 (1/2)]. The volunteers were given a fatty meal containing 1 g fat/kg of body weight, 60,000 IU of vitamin A per m2 of body surface and 7 mg of cholesterol/kg of body weight), with 60% of calories as fat, 15% as proteins and 25% as carbohydrates. Blood samples were taken at time 0, every hour until hour 6 and every 2 h and 30 min until hour 11 to determine concentrations of cholesterol, triglycerides, apo A-1 and apo B.Forty-seven normolipidemic volunteers who were homozygotes for the e3 allele of apolipoprotein (apo) e were selected [37 homozygotes for allele 1 of the SR-BI (1/1) gene and 10 heterozygotes for allele 2 (1/2)]. The volunteers were given a fatty meal containing 1 g fat/kg of body weight, 60,000 IU of vitamin A per m2 of body surface and 7 mg of cholesterol/kg of body weight), with 60% of calories as fat, 15% as proteins and 25% as carbohydrates. Blood samples were taken at time 0, every hour until hour 6 and every 2 h and 30 min until hour 11 to determine concentrations of cholesterol, triglycerides, apo A-1 and apo B.

Results

Interaction between the presence of polymorphism exon 1 variant at the SR-BI gene locus and total triglyceride levels was observed according to time (p = 0.029). Thus, carriers of allele 2 (1/2) presented a later curve, suggesting slower intestinal triglyceride absorption than homozygotes 1/1.

Conclusions

Our data suggest that carriers of the minority allele 2 with genotype 1/2 present slower intestinal triglyceride absorption, which could explain the individual variability observed in postprandial lipemic response.

Key words:
Scavenger receptor class B type I
Postprandial lipemia
Lipaemia
Genetics
Cardiovascular risk
Full text is only aviable in PDF
Bibliografía
[1.]
J.R. Patsch, G. Miesenbock, T. Hopferwieser, V. Muhlberger, E. Knapp, J.K. Dunn, et al.
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.
Arterioscler Thromb Vasc Biol, 12 (1992), pp. 1336-1345
[2.]
K. Kugiyama, H. Doi, K. Takazoe, H. Kawano, H. Soejima, Y. Mizuno, et al.
Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease.
Circulation, 99 (1999), pp. 2858-2860
[3.]
M.A. Ostos, J. López-Miranda, J.M. Ordovás, C. Marín, A. Blanco, P. Castro, et al.
Dietary fat clearance is modulated by genetic variation in apolipoprotein A-IV gene locus.
J Lipid Res, 39 (1998), pp. 2439-2500
[4.]
M.A. Ostos, J. López-Miranda, C. Marín, P. Castro, P. Gómez, E. Paz, et al.
The apolipoprotein A-IV-360 His polymorphism determines the dietary fat clearance in normal subjects.
Atherosclerosis, 153 (2000), pp. 209-217
[5.]
J.M. Ordovás.
Genetics, postprandial lipemia and obesity.
Nutr Metab Cardiovasc Dis, 11 (2001), pp. 118-133
[6.]
J.J. Agren, R. Valve, H. Vidgren, M. Laakso, M. Uusitupa.
Postprandial lipemic response is modified by the polimorphism at codon 54 of the fatty acid-binding protein 2 gene.
Arterioscler Thromb Vasc Biol, 18 (1998), pp. 1606-1610
[7.]
Q. Zhang, E. Cavallero, M.M. Hoffmann, J. Cabaña, A. Kay, A. Charles, et al.
Mutations at the lipoprotein lipase gene locus in subjects with diabetes mellitus, obesity and lipaemia.
Clin Sci, 93 (1997), pp. 270-274
[8.]
T. Van Berkel, M. Van Eck, N. Herijgers, K. Fluiter, S. Nion.
Scavenger receptor classes A and B: their roles in atherogenesis and metabolism of modified LDL and HDL.
Ann N Y Acad Sci, 902 (2000), pp. 113-127
[9.]
S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs, K. Krieger.
Identification of scavenger receptor SR-BI as a high density lipoprotein receptor.
Science, 271 (1996), pp. 518-520
[10.]
M. Krieger.
Scavenger receptor class B type I is a multiligand HDL receptor that influence diverse physiologic systems.
J Clin Invest, 108 (2001), pp. 793-797
[11.]
K.F. Kozarsky, M.H. Donahee, J.M. Glick, M. Krieger, D.J. Rader.
Gene transfer and hepatic overexpression of the HDL receptor SR BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 721-727
[12.]
T. Arai, N. Wang, M. Bezouevski, C. Welch, A.R. Tall.
Decreased atherosclerosis in heterozygous low density lipoprotein receptor deficient mice expressing the scavenger receptor BI transgene.
J Biol Chem, 274 (1999), pp. 2366-2371
[13.]
S. Acton, D. Osgood, M. Donoghue, D. Corella, M. Pocovi, A. Cenarro, et al.
Association of the polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population.
Arterioscler Thromb Vasc Biol, 19 (1999), pp. 1734-1743
[14.]
P. Pérez-Martínez, J.M. Ordovás, J. López-Miranda, P. Gómez, C. Marín, J. Moreno, et al.
Polymorphism of exon 1 variant at the SR BI gene locus, influence on LDL cholesterol plasma levels during the consumption of diets with different fat content in healthy subjects.
Am J Clin Nutr, 77 (2003), pp. 809-813
[15.]
H. Hauser, J.H. Dyer, A. Nandy, M.A. Vega, M. Werder, E. Bieliauskaite, et al.
Identification of a receptor mediating absortion of dietary cholesterol in the intestine.
Biochemistry, 37 (1998), pp. 17843-17850
[16.]
K. Kontula, K. Aalto-Setala, T. Kuusi, L. Hamalainen, A.C. Syvanen.
Apolipoprotein E polymorphism determined by restriction enzyme analysis of DNA amplified by polymerase chain reaction: convenient alternative to phenotyping by isoelectric focusing.
Clin Chem, 36 (1990), pp. 2087-2092
[17.]
E. Boerwinkle, S. Brown, A.R. Sharrett, G. Heiss, W. Patsch.
Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations.
Am J Hum Genet, 54 (1994), pp. 341-360
[18.]
G. Bucolo, H. David.
Quantitative determination of serum triglycerides by use of enzymes.
Clin Chem, 19 (1973), pp. 476-482
[19.]
C.C. Allain, L.S. Poon, C.S.G. Chang, W. Richmond, P.C. Fu.
Enzymatic determination of total serum cholesterol.
Clin Chem, 20 (1974), pp. 470-475
[20.]
P. Riepponen, J. Marniemi, T. Rautaoja.
Immunoturbidimetric determination of apolipoproteins A-I and B in serum.
Scand J Clin Lab Invest, 47 (1987), pp. 739-744
[21.]
R. Warnick, J. Benderson, J.J. Albers.
Dextran sulfate-Mg precipitation procedure for quantitation of high density lipoprotein cholesterol.
Clin Chem, 28 (1982), pp. 1379-1388
[22.]
W.T. Friedewald, R.I. Levy, D.S. Fredrickson.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of a preparative ultracentrifugue.
Clin Chem, 18 (1972), pp. 499-502
[23.]
D. Osgood-McWeeney, J. Galluzzi, J.M. Ordovás.
Allelic discrimination for single nucleotide polymorphisms in the human scavenger receptor class B type 1 gene locus using fluorescent probes.
Clin Chem, 46 (2000), pp. 118-119
[24.]
C. Marín, J. López Miranda, P. Gómez, E. Paz, P. Pérez Martínez, F. Fuentes, et al.
Effects of the human apolipoprotein A-I promoter G-A mutation on postprandial lipoprotein metabolism.
Am J Clin Nutr, 76 (2002), pp. 319-325
[25.]
J. López Miranda, J.M. Ordovás, M.A. Ostos, C. Marín, S. Jansen, J. Salas, et al.
Dietary fat clearance in normal subjects is modulated by genetic variation at the apolipoprotein B gene locus.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 1765-1773
[26.]
B.J. Brenninkmeijer, P.M.J. Stuyt, P.N.M. Demacker, A.F.H. Stalenhoef, A. Van’t Laar.
Catabolism of chylomicron remnants in normolipedic subjects in relation to the apoprotein E phenotype.
J Lip Res, 28 (1987), pp. 361-370
[27.]
M.S. Weintraub, S. Eisenberg, J.L. Breslow.
Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.
J Clin Invest, 80 (1987), pp. 1571-1577
[28.]
S. Swarnakar, R.E. Temel, M.A. Connelly, S. Azhar, D.L. Williams.
Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester.
J Biol Chem, 274 (1999), pp. 29733-29739
[29.]
A. Rigotti.
Importancia del receptor scavenger clase B, tipo I (SRBI) en el metabolismo de las HDL y en la aterosclerosis.
Clin Invest Arterioscler, 12 (2000), pp. 219-231
[30.]
P.S. Roheim, B.F. Asztalos.
Clinical significance of lipoprotein size and risk for coronary atherosclerosis.
Clin Chem, 41 (1995), pp. 147-152
[31.]
A. Chait, R.L. Brazg, D.L. Tribble, R.M. Krauss.
Susceptibility of small, dense, low-density lipoprotein to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.
Am J Med, 94 (1993), pp. 350-356
[32.]
L.A. Sala Álvarez, M. Valderrama, J.A. Gómez Gerique, P. Agudo, F.J. Torres, F.J. Rodríguez Gorostiza, et al.
Importancia de nuevos marcadores de riesgo cardiovascular.
Clin Invest Arterioscler, 13 (2001), pp. 14-27
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos